Chapter title |
Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor
|
---|---|
Chapter number | 14 |
Book title |
Small Molecules in Hematology
|
Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2018
|
DOI | 10.1007/978-3-319-91439-8_14 |
Pubmed ID | |
Book ISBNs |
978-3-31-991438-1, 978-3-31-991439-8
|
Authors |
Katharina Kriegsmann, Mark Kriegsmann, Mathias Witzens-Harig, Kriegsmann, Katharina, Kriegsmann, Mark, Witzens-Harig, Mathias |
Abstract |
The Bruton's tyrosine kinase (BTK) is an essential in the B-cell receptor (BCR) signaling pathway which was identified as crucial in the pathogenesis of B-cell malignancies. Ibrutinib, a first-in-class BTK inhibitor, has been approved for the treatment of distinct B-cell malignancies. To overcome off-target side effects of and emerging resistances to ibrutinib, more selective second-generation BTK inhibitors were developed. Acalabrutinib is a novel second-generation BTK inhibitor and has shown promising safety and efficacy profiles in phase 1/2 clinical trials in patients with relapsed CLL and pretreated MCL. Recently, acalabrutinib was approved by the FDA for treatment of adult patients with MCL who received at least one prior therapy. However, clinical trials on a direct comparison between ibrutinib and acalabrutinib and on combination treatment options with other agents as CD20 antibodies are warranted. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 17 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 3 | 18% |
Other | 2 | 12% |
Student > Doctoral Student | 2 | 12% |
Researcher | 2 | 12% |
Student > Ph. D. Student | 1 | 6% |
Other | 1 | 6% |
Unknown | 6 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 12% |
Biochemistry, Genetics and Molecular Biology | 2 | 12% |
Immunology and Microbiology | 2 | 12% |
Agricultural and Biological Sciences | 2 | 12% |
Chemical Engineering | 1 | 6% |
Other | 2 | 12% |
Unknown | 6 | 35% |